for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Qiagen NV

QIA.DE

Latest Trade

33.78EUR

Change

-0.22(-0.65%)

Volume

105,486

Today's Range

33.74

 - 

34.32

52 Week Range

22.54

 - 

39.19

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
34.00
Open
34.30
Volume
105,486
3M AVG Volume
13.04
Today's High
34.32
Today's Low
33.74
52 Week High
39.19
52 Week Low
22.54
Shares Out (MIL)
227.75
Market Cap (MIL)
7,957.53
Forward P/E
--
Dividend (Yield %)
--

Next Event

Qiagen NV at Credit Suisse Global Healthcare Conference

Latest Developments

More

Qiagen Q4 Net Sales Up At $413.5 Million

Qiagen Builds On Global Collaboration With Amgen For Companion Diagnostic Development In Non-Small Cell Lung Cancer

Qiagen Says Concludes Strategic Alternatives Review

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Qiagen NV

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

Contact Info

Hulsterweg 82

+31.77.3556600

https://www.qiagen.com/

Executive Leadership

Hakan Bjorklund

Independent Chairman of the Supervisory Board

Thierry Bernard

Interim Chief Executive Officer, Member of the Executive Committee

Roland Sackers

Managing Director, Chief Financial Officer, Member of the Executive Committee

Barthold Piening

Senior Vice President, Head of Global Operations, Member of the Executive Committee

Annette Koch

Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee

Key Stats

2.71 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

1.4K

2018

1.5K

2019

1.5K

2020(E)

1.6K
EPS (USD)

2017

1.270

2018

1.340

2019

1.430

2020(E)

1.519
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.65
Price To Book (MRQ)
3.33
Price To Cash Flow (TTM)
45.41
Total Debt To Equity (MRQ)
67.27
LT Debt To Equity (MRQ)
56.02
Return on Investment (TTM)
-0.92
Return on Equity (TTM)
-0.75

Latest News

Latest News

German stocks - Factors to watch on February 20

The following are some of the factors that may move German stocks on Thursday:

BRIEF-Qiagen's QuantiFERON®-TB Gold Plus To Be Adopted For Latent TB Testing In Nigeria

* QIAGEN’S QUANTIFERON®-TB GOLD PLUS TO BE ADOPTED FOR LATENT TB TESTING IN NIGERIA

Breakingviews-Epidemics are tough to turn into profit

Epidemics are catastrophic for humans, and it turns out they aren’t much better for healthcare companies. The number of confirmed cases of the new coronavirus has multiplied more than 80-fold over three weeks despite measures such as travel bans, and exceeded 45,000 across...

Qiagen expects coronavirus test to be ready this month: CEO

Genetic testing specialist Qiagen <QIA.DE> should have a targeted test for the coronavirus ready this month and is extremely active in providing products to disease control institutions in China, its interim CEO said on Wednesday.

German stocks - Factors to watch on February 5

The following are some of the factors that may move German stocks on Wednesday:

UPDATE 1-Qiagen beats Q4 growth consensus after streamlining operations

Genetic testing specialist Qiagen beat analysts' expectations for quarterly sales and profit growth on Tuesday, citing savings generated after its decision to stop developing new next-generation sequence (NGS) instruments.

Qiagen beats Q4 growth consensus after streamlining operations

Genetic testing specialist Qiagen beat analysts' expectations for quarterly sales and profit growth on Tuesday, citing positive outcomes after its decision to stop developing new next-generation sequence (NGS) instruments.

German stocks - Factors to watch on February 4

The following are some of the factors that may move German stocks on Tuesday:

German stocks - Factors to watch on January 14

The following are some of the factors that may move German stocks on Tuesday:

European markets ends festive week at fresh record highs

European stocks wrapped up a holiday-thinned week at record highs on Friday as growing hopes that a Sino-U.S. trade deal would be inked soon, as well as the latest dose of upbeat China data supported prospects of an improving global growth.

Festive European markets notch another record high

European shares rose to another record high on Friday, as investors remained optimistic about an improving global economy after a fresh dose of upbeat economic data from China and firming indications of a preliminary U.S.-China trade deal.

German stocks - Factors to watch on December 27

The following are some of the factors that may move German stocks on Friday:

Qiagen decides against sale following review, shares fall

Genetic testing firm Qiagen NV <QIA.DE> <QGEN.N> said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.

Qiagen decides against sale following review

Genetic testing firm Qiagen NV said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.

Siemens Healthineers says has no interest in buying Qiagen

German health technology company Siemens Healthineers is not interested in a takeover of Qiagen, the genetic testing company which last month said it would start talks with several potential suitors.

European stocks end flat as defensive gains offset auto slide

European stocks ended flat on Monday as a spurt of defensive buying over uncertainty surrounding U.S.-China trade talks helped temper losses in the auto sector.

CORRECTED-UPDATE 1-European stocks stall as auto tariff worries weigh

A bidding war for Spanish bourse BME and gains in defensive stocks propped up European markets on Monday, although doubts on whether or not the United States will impose tariffs on EU carmakers weighed on shares.

Qiagen shares surge as diagnostics group says open to takeover talks

Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors.

European shares extend winning streak; Qiagen jumps as company explores sale

European shares edged closer to a record level on Monday, as optimism around U.S.-China trade talks and a surprise move by China's central bank in cutting a key interest rate painted an upbeat picture about global growth.

German stocks - Factors to watch on November 18

The following are some of the factors that may move German stocks on Monday:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up